Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-50,300
Closed -$22.7K 14254
2025
Q2
$22.7K Buy
50,300
+36,000
+252% +$15.7K ﹤0.01% 12076
2025
Q1
$5.82K Sell
14,300
-52,100
-78% -$33.4K ﹤0.01% 13789
2024
Q4
$44K Buy
66,400
+600
+0.9% +$417 ﹤0.01% 12528
2024
Q3
$55.9K Sell
65,800
-6,100
-8% -$4.66K ﹤0.01% 11788
2024
Q2
$48K Buy
71,900
+5,700
+9% +$4.73K ﹤0.01% 11807
2024
Q1
$86.1K Sell
66,200
-113,300
-63% -$119K ﹤0.01% 11557
2023
Q4
$103K Sell
179,500
-1,900
-1% -$1.31K ﹤0.01% 10901
2023
Q3
$137K Sell
181,400
-33,400
-16% -$25.4K ﹤0.01% 10497
2023
Q2
$157K Sell
214,800
-24,500
-10% -$22.8K ﹤0.01% 10271
2023
Q1
$181K Sell
239,300
-240,000
-50% -$223K ﹤0.01% 10346
2022
Q4
$461K Sell
479,300
-300
-0.1% -$424 ﹤0.01% 8416
2022
Q3
$1.05M Sell
479,600
-91,700
-16% -$316K ﹤0.01% 6891
2022
Q2
$2M Sell
571,300
-1,500
-0.3% -$5.6K ﹤0.01% 5547
2022
Q1
$2.89M Buy
572,800
+20,300
+4% +$103K ﹤0.01% 5282
2021
Q4
$3.46M Sell
552,500
-43,700
-7% -$298K ﹤0.01% 5058
2021
Q3
$4.74M Sell
596,200
-164,100
-22% -$1.35M ﹤0.01% 4404
2021
Q2
$5.7M Buy
760,300
+255,500
+51% +$1.78M ﹤0.01% 4155
2021
Q1
$3.05M Sell
504,800
-108,300
-18% -$833K ﹤0.01% 5400
2020
Q4
$3.5M Buy
613,100
+156,400
+34% +$995K ﹤0.01% 4315
2020
Q3
$3.04M Buy
+456,700
New +$4.07M ﹤0.01% 3970

Other funds holding VXRT

Citadel Advisors's VXRT Position: Q1 2025 in Review

Citadel Advisors sold out of Vaxart (VXRT) in Q1 2025, closing a stake of 501,623 shares — an estimated $322K sold.

Citadel Advisors first reported a position in VXRT in Q1 2014 and held it in 23 quarters. The position peaked at $27.4M in Q2 2020. 92 funds tracked by Wall St. Rank hold VXRT as of Q1 2025.

  • Citadel Advisors reported no remaining Vaxart position as of Q1 2025 after selling out during the quarter.
  • Citadel Advisors sold 501,623 Vaxart shares in Q1 2025, an estimated $322K.
  • Citadel Advisors first reported a position in Vaxart in Q1 2014 and held it in 23 quarters.
  • Citadel Advisors's Vaxart position peaked at $27.4M in Q2 2020.
  • 92 funds tracked by Wall St. Rank held Vaxart as of Q1 2025.

Based on Citadel Advisors's 13F filing for Q1 2025, filed 15 May 2025.